Skip to main content

Edoardo Caronna

Institutions of which they are part

Postdoctoral researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Edoardo Caronna

Institutions of which they are part

Postdoctoral researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Projects

Digitalization in Migraine

IP: Patricia Pozo Rosich
Collaborators: Edoardo Caronna, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 180000
Reference: JR23/00065
Duration: 01/01/2024 - 31/12/2027

(PREDIMIGRAINE) Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti-CGRP utilizando estrategias multi-ómicas.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 369930
Reference: PMP22/00189
Duration: 01/01/2023 - 31/12/2025

BiOmarcadores Moleculares y clínicos de respuesta al tratamiento en los Ataques de Migraña (Estudio MAMBO).

IP: Marta Torres Ferrús
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Victor José Gallardo Lopez, Edoardo Caronna, Laura Gómez Dabó
Funding agency: Instituto de Salud Carlos III
Funding: 75020
Reference: PI22/01530
Duration: 01/01/2023 - 31/12/2025

Cefalea i dolor neurològic

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour, Eulalia Gine Cipres, Marta Torres Ferrús, Victor José Gallardo Lopez, Nara Ikumi Montserrat, Marta Vila Pueyo, Edoardo Caronna
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 0.01
Reference: 2021 SGR 00406
Duration: 01/01/2022 - 30/06/2025

Related news

Two international studies led by Vall d'Hebron recommend early administration of specific drugs to prevent migraine to achieve a better response to therapy.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

The study, conducted in more than 770 people, concludes that atogepant reduces the frequency of migraine attacks and the need to take medication.

Related professionals

Mª Eulàlia Joseph Munné

Mª Eulàlia Joseph Munné

Medium Grade Technician
General Services and Infrastructures Unit
Manager
Read more
Roser Navarro García

Roser Navarro García

Infectious Diseases
Read more
Mª Carmen López  Arribas

Mª Carmen López Arribas

Research technician
Molecular Medical Imaging
Read more
Esther Puig Rodriguez

Esther Puig Rodriguez

Medium Grade Technician
Purchase and Biddings Unit
Finance Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.